Matulonis UA, Vergote I, Moore KN, Martin LP, Castro CM, Gilbert L, Xia Y, Method M, Stec J, Birrer MJ, O'Malley DM. Safety and efficacy of mirvetuximab soravtansine, a folate receptor alpha (FRa)-targeting antibody-drug conjugate (ADC), in combination with pembrolizumab in patients with platinum-resistant ovarian cancer. Gynecol Oncol. 2025 Sep; 200:96-104.